Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study
The primary objective of this study was to conduct a cost–utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish ho...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/12/10/244 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850204591960883200 |
|---|---|
| author | José Seijas-Amigo Maria José Mauriz-Montero Pedro Suarez-Artime Mónica Gayoso-Rey Francisco Reyes-Santías Ana Estany-Gestal Antonia Casas-Martínez Lara González-Freire Ana Rodriguez-Vazquez Natalia Pérez-Rodriguez Laura Villaverde-Piñeiro Concepción Castro-Rubinos Esther Espino-Paisán Octavio Cordova-Arevalo Diego Rodriguez-Penas Begoña Cardeso-Paredes Marta Ribeiro-Ferreiro Moisés Rodríguez-Mañero Alberto Cordero José R. González-Juanatey MEMOGAL Investigators |
| author_facet | José Seijas-Amigo Maria José Mauriz-Montero Pedro Suarez-Artime Mónica Gayoso-Rey Francisco Reyes-Santías Ana Estany-Gestal Antonia Casas-Martínez Lara González-Freire Ana Rodriguez-Vazquez Natalia Pérez-Rodriguez Laura Villaverde-Piñeiro Concepción Castro-Rubinos Esther Espino-Paisán Octavio Cordova-Arevalo Diego Rodriguez-Penas Begoña Cardeso-Paredes Marta Ribeiro-Ferreiro Moisés Rodríguez-Mañero Alberto Cordero José R. González-Juanatey MEMOGAL Investigators |
| author_sort | José Seijas-Amigo |
| collection | DOAJ |
| description | The primary objective of this study was to conduct a cost–utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients with hypercholesterolemia or atherosclerotic cardiovascular disease. This study assessed health-related quality of life (QoL) using the EQ-5D-3L questionnaire. The cost–utility analysis evaluated the economic impact of PCSK9 inhibitors when used with standard care compared to standard care alone, calculating the incremental cost–effectiveness ratio (ICER). This study included 158 patients with an average age of 61 years, male (66.5%). For patients initiating PCSK9 inhibitors, the treatment cost was EUR 13,633.39, while standard therapy cost EUR 3638.25 over two years. QoL for PCSK9 inhibitors stood at 1.6489 over two years, compared to 1.4548 for standard therapy. The results revealed favorable cost–utility outcomes, with an ICER of EUR 51,427.72. Significant improvements were observed in the domains of mobility, self-care, daily activities, pain/discomfort, and anxiety/depression (<i>p</i> < 0.001). This study presents the first real-world cost–utility analysis of PCSK9 inhibitors, supporting their economic rationale and highlighting their benefits in clinical practice. Healthcare decision-makers can use these results to inform their decisions and reimbursement policies concerning PCSK9 inhibitors. Trial Registration clinicaltrials.gov Identifier: NCT04319081. |
| format | Article |
| id | doaj-art-5f7b5f76f0bb48bbbf874536a08de5ff |
| institution | OA Journals |
| issn | 2079-9721 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diseases |
| spelling | doaj-art-5f7b5f76f0bb48bbbf874536a08de5ff2025-08-20T02:11:15ZengMDPI AGDiseases2079-97212024-10-01121024410.3390/diseases12100244Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized StudyJosé Seijas-Amigo0Maria José Mauriz-Montero1Pedro Suarez-Artime2Mónica Gayoso-Rey3Francisco Reyes-Santías4Ana Estany-Gestal5Antonia Casas-Martínez6Lara González-Freire7Ana Rodriguez-Vazquez8Natalia Pérez-Rodriguez9Laura Villaverde-Piñeiro10Concepción Castro-Rubinos11Esther Espino-Paisán12Octavio Cordova-Arevalo13Diego Rodriguez-Penas14Begoña Cardeso-Paredes15Marta Ribeiro-Ferreiro16Moisés Rodríguez-Mañero17Alberto Cordero18José R. González-Juanatey19MEMOGAL InvestigatorsCardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, SpainPharmacy Department, Complejo Hospitalario Universitario A Coruña, 15006 A Coruña, SpainPharmacy Department, Complejo Hospitalario Universidad de Santiago de Compostela, 15782 Santiago de Compostela, SpainPharmacy Department, Complejo Hospitalario Universitario de Vigo, 36312 Vigo, SpainManagement Department, Complejo Hospitalario Universidad de Santiago de Compostela, 15782 Santiago de Compostela, SpainFundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, SpainPharmacy Department, Complejo Hospitalario Universitario de Ferrol, 15405 Ferrol, SpainPharmacy Department, Complejo Hospitalario Universitario de Pontevedra, 36472 Pontevedra, SpainPharmacy Department, Complejo Hospitalario Universitario de Ourense, 32005 Ourense, SpainPharmacy Department, Complejo Hospitalario Universitario de Lugo, 27003 Lugo, SpainPharmacy Department, Hospital Comarcal de Monforte, 27400 Monforte de Lemos, SpainPharmacy Department, Hospital Público da Mariña, 27880 Burela, SpainPharmacy Department, Hospital do Barbanza, 15993 A Coruña, SpainPEMEX, Universidade de Vigo, 36310 Vigo, SpainCardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, SpainCardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, SpainCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, SpainCardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, SpainThe primary objective of this study was to conduct a cost–utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients with hypercholesterolemia or atherosclerotic cardiovascular disease. This study assessed health-related quality of life (QoL) using the EQ-5D-3L questionnaire. The cost–utility analysis evaluated the economic impact of PCSK9 inhibitors when used with standard care compared to standard care alone, calculating the incremental cost–effectiveness ratio (ICER). This study included 158 patients with an average age of 61 years, male (66.5%). For patients initiating PCSK9 inhibitors, the treatment cost was EUR 13,633.39, while standard therapy cost EUR 3638.25 over two years. QoL for PCSK9 inhibitors stood at 1.6489 over two years, compared to 1.4548 for standard therapy. The results revealed favorable cost–utility outcomes, with an ICER of EUR 51,427.72. Significant improvements were observed in the domains of mobility, self-care, daily activities, pain/discomfort, and anxiety/depression (<i>p</i> < 0.001). This study presents the first real-world cost–utility analysis of PCSK9 inhibitors, supporting their economic rationale and highlighting their benefits in clinical practice. Healthcare decision-makers can use these results to inform their decisions and reimbursement policies concerning PCSK9 inhibitors. Trial Registration clinicaltrials.gov Identifier: NCT04319081.https://www.mdpi.com/2079-9721/12/10/244PCSK9 inhibitorscost–utility analysisquality of lifereal-world studycardiovascular disease |
| spellingShingle | José Seijas-Amigo Maria José Mauriz-Montero Pedro Suarez-Artime Mónica Gayoso-Rey Francisco Reyes-Santías Ana Estany-Gestal Antonia Casas-Martínez Lara González-Freire Ana Rodriguez-Vazquez Natalia Pérez-Rodriguez Laura Villaverde-Piñeiro Concepción Castro-Rubinos Esther Espino-Paisán Octavio Cordova-Arevalo Diego Rodriguez-Penas Begoña Cardeso-Paredes Marta Ribeiro-Ferreiro Moisés Rodríguez-Mañero Alberto Cordero José R. González-Juanatey MEMOGAL Investigators Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study Diseases PCSK9 inhibitors cost–utility analysis quality of life real-world study cardiovascular disease |
| title | Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study |
| title_full | Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study |
| title_fullStr | Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study |
| title_full_unstemmed | Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study |
| title_short | Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study |
| title_sort | cost utility analysis of pcsk9 inhibitors and quality of life a two year multicenter non randomized study |
| topic | PCSK9 inhibitors cost–utility analysis quality of life real-world study cardiovascular disease |
| url | https://www.mdpi.com/2079-9721/12/10/244 |
| work_keys_str_mv | AT joseseijasamigo costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT mariajosemaurizmontero costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT pedrosuarezartime costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT monicagayosorey costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT franciscoreyessantias costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT anaestanygestal costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT antoniacasasmartinez costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT laragonzalezfreire costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT anarodriguezvazquez costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT nataliaperezrodriguez costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT lauravillaverdepineiro costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT concepcioncastrorubinos costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT estherespinopaisan costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT octaviocordovaarevalo costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT diegorodriguezpenas costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT begonacardesoparedes costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT martaribeiroferreiro costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT moisesrodriguezmanero costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT albertocordero costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT josergonzalezjuanatey costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy AT memogalinvestigators costutilityanalysisofpcsk9inhibitorsandqualityoflifeatwoyearmulticenternonrandomizedstudy |